☆ 4.6 Review

Immune-checkpoint inhibitors: long-term implications of toxicity

NATURE REVIEWS CLINICAL ONCOLOGY (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

FDG-PET to predict long-term outcome from anti-PD-1 therapy in metastatic melanoma

F. Dimitriou et al.

Summary: In a retrospective analysis of 104 patients treated with PD-1 inhibitors, the majority maintained stable responses at 5 years, particularly those with CMR. PET was found to be a better predictor of progression than CT, especially in patients with residual disease on CT. Despite progression events, patients with solitary sites of progression managed locally had excellent long-term overall survival rates.

ANNALS OF ONCOLOGY (2022)

添加到收藏夹

Article Oncology

The Impact of Beta Blockers on Survival Outcomes in Patients With Non-small-cell Lung Cancer Treated With Immune Checkpoint Inhibitors

Michael S. Oh et al.

Summary: This study found that the use of beta blockers in lung cancer patients undergoing immunotherapy was associated with improved progression free survival. Stress signaling in anti-cancer immunity was highlighted, suggesting that this treatment strategy should be further explored in prospective studies.

CLINICAL LUNG CANCER (2021)

添加到收藏夹

Review Ophthalmology

Immune Checkpoint Inhibitor-associated Uveitis: Review of Treatments and Outcomes

Eliot R. Dow et al.

Summary: ICPIs were associated with 126 cases of anterior uveitis, intermediate uveitis, posterior uveitis, and panuveitis from 67 reports in the literature. Patients typically developed intraocular inflammation a median of 9 weeks after initiation of ICPI and 83.6% of the patients developed uveitis within 6 months. The vast majority of patients recovered to within one line of baseline vision in response to topical, local, and/or systemic steroid treatment as well as the cessation of medication. Prompt recognition and steroid treatment of ICPIU are critical to the care of patients receiving ICPIs.

OCULAR IMMUNOLOGY AND INFLAMMATION (2021)

添加到收藏夹

Review Pharmacology & Pharmacy

The potential for immune checkpoint modulators in cerebrovascular injury and inflammation

Jennifer E. Kim et al.

Summary: This review discusses the role of immune checkpoints in neuroinflammation and highlights the potential of therapeutic immune checkpoint modulation in inflammatory cerebrovascular disorders. The clinical potential of checkpoint-based immunotherapy in human cancers shows promising applications for immune checkpoint modulation in neuroinflammation.

EXPERT OPINION ON THERAPEUTIC TARGETS (2021)

添加到收藏夹

Editorial Material Rheumatology

Spectrum and impact of checkpoint inhibitor-induced irAEs

Laura C. Cappelli et al.

Summary: Immune checkpoint inhibitors can lead to immune-related adverse events that resemble rheumatic diseases, impacting morbidity and mortality significantly. Early recognition, systemic immunosuppression, and multidisciplinary care are crucial for managing these events and improving patient outcomes.

NATURE REVIEWS RHEUMATOLOGY (2021)

添加到收藏夹

Article Oncology

A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitors-Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention

Spencer C. Wei et al.

Summary: This study presents a robust preclinical model of ICI-associated myocarditis that recapitulates the clinical syndrome. Using this model, researchers demonstrate that CTLA4 and PD-1 (ICI targets) functionally interact in the development of myocarditis, and intervention with CTLA4-Ig (abatacept) attenuates myocarditis, providing mechanistic rationale and preclinical support for therapeutic clinical studies.

CANCER DISCOVERY (2021)

添加到收藏夹

Article Oncology

Peripheral T cell receptor repertoire features predict durable responses to anti-PD-1 inhibitor monotherapy in advanced renal cell carcinoma

Taigo Kato et al.

Summary: In this study, researchers analyzed peripheral blood and tumor tissue samples from patients with advanced kidney cancer before and after PD-1 treatment and found an expansion of specific T cell clones in the peripheral blood of responders post-treatment, indicating a possible correlation with tumor-infiltrating T cells.

ONCOIMMUNOLOGY (2021)

添加到收藏夹

Article Oncology

Outcomes of Patients With Interstitial Lung Disease Receiving Programmed Cell Death 1 Inhibitors: A Retrospective Case Series

Ioana A. Dobre et al.

Summary: This study found that patients with ILD receiving PD-1 inhibitors more frequently died from cancer-related causes than from ILD. Further research is needed to determine the safety of ICIs in patients with ILD and if ILD subtype may help to refine ICI-associated risks.

CLINICAL LUNG CANCER (2021)

添加到收藏夹

Letter Oncology

The positive effect of immune checkpoint inhibitor-induced thyroiditis on overall survival accounting for immortal time bias: a retrospective cohort study of 6596 patients

S. Street et al.

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Delayed immune-related adverse events with an PD-1-based immunotherapy in melanoma

C. N. Owen et al.

Summary: This study revealed that delayed irAEs occur in approximately 5.3% of patients receiving anti-PD-1-based therapy, with common manifestations including colitis, rash, and pneumonitis. Some patients may experience severe symptoms and even death as a result of delayed irAEs.

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Article Dermatology

Effect of dermatological consultation on survival in patients with checkpoint inhibitor-associated cutaneous toxicity

L. L. Thompson et al.

Summary: Dermatologist-evaluated cirAEs were more likely to receive treatment than non-referred cirAEs, and patients receiving any cirAE treatment showed improved survival outcomes.

BRITISH JOURNAL OF DERMATOLOGY (2021)

添加到收藏夹

Review Biotechnology & Applied Microbiology

Combining anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) and -programmed cell death protein 1 (PD-1) agents for cancer immunotherapy

Selina K. Wong et al.

Summary: This article explores the combination therapy of anti-CTLA-4 and anti-PD-1 antibodies in advanced malignancies, discussing the biological rationale, treatment schedules, toxicity profiles, and potential for use in different disease settings. It also anticipates the shift towards this combination therapy becoming a standard treatment for cancer patients.

EXPERT OPINION ON BIOLOGICAL THERAPY (2021)

添加到收藏夹

Article Oncology

Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy

Briana Rose Halle et al.

Summary: A retrospective cohort study on patients with pre-existing psoriasis receiving ICIs for cancer treatment showed that most patients experienced psoriasis exacerbation after treatment, but it was manageable with standard therapies; some patients also experienced other immune-related adverse events; patients with disease exacerbation performed well in terms of progression-free survival compared to those who did not.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

添加到收藏夹

Article Endocrinology & Metabolism

Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment

Christopher A. Muir et al.

Summary: Thyroid dysfunction is common following immune checkpoint inhibition, with different subtypes of thyroid immune-related adverse events having unique clinical and biochemical associations. Overt thyrotoxicosis was associated with longer progression free survival and overall survival, while hypothyroidism showed no association with cancer outcomes. Multiple distinct phenotypes of thyroid irAEs suggest potentially different etiologies for thyrotoxicosis and hypothyroidism.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2021)

添加到收藏夹

Article Oncology

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%

Martin Reck et al.

Summary: This study reports the first 5-year follow-up of a first-line immunotherapy trial for NSCLC, demonstrating that pembrolizumab provides a durable, clinically meaningful long-term overall survival benefit in first-line treatment of metastatic NSCLC with a PD-L1 tumor proportion score of at least 50%.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma

Daniel J. Olson et al.

Summary: This study is the first prospective study in melanoma of pembrolizumab plus low-dose ipilimumab after anti-PD-1/L1 immunotherapy failure, demonstrating significant antitumor activity and tolerability.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Review Oncology

Immune Checkpoint Inhibitor-related Guillain-Barre Syndrome: A Case Series and Review of the Literature

Jorien B. E. Janssen et al.

Summary: Immune checkpoint inhibitors (ICIs) have shown promising clinical outcomes in various malignancies, but can lead to serious immune-related adverse events, including rare but life-threatening neurological events like Guillain-Barre syndrome (GBS). Treatment for ICI-related GBS mostly involves concurrent use of IVIg and steroids, resulting in clinical improvement in the majority of cases.

JOURNAL OF IMMUNOTHERAPY (2021)

添加到收藏夹

Article Oncology

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

Alexander M. M. Eggermont et al.

Summary: The study demonstrated that adjuvant pembrolizumab therapy can improve the 3.5-year distant metastasis-free survival in patients with resected high-risk stage III cutaneous melanoma, with a more significant effect in patients with PD-L1-positive tumors.

LANCET ONCOLOGY (2021)

添加到收藏夹

Review Multidisciplinary Sciences

The changing landscape of atherosclerosis

Peter Libby

Summary: Emerging evidence has led to a significant evolution of concepts related to atherosclerosis, with a shifting risk profile that is no longer limited to specific regions or demographics. Recent research has highlighted new risk factors and mechanisms underlying atherosclerosis, opening doors to potential therapeutic interventions for this widespread disease.

NATURE (2021)

添加到收藏夹

Article Cell Biology

CD4+ T cells are essential for the development of destructive thyroiditis induced by anti-PD-1 antibody in thyroglobulin-immunized mice

Yoshinori Yasuda et al.

Summary: The study found that CD4(+) T cells play a critical role in the development of destructive thyroiditis, and depletion of CD4(+) T cells can completely prevent the occurrence of the disease.

SCIENCE TRANSLATIONAL MEDICINE (2021)

添加到收藏夹

Article Oncology

Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-risk Resected Melanoma

J. Randall Patrinely et al.

Summary: This multicenter cohort study found that chronic immune-related adverse events (irAEs) associated with anti-PD-1 therapy were more common than previously recognized, with a considerable proportion of patients developing chronic irAEs such as endocrinopathies and arthritis. Visceral organ-related irAEs had lower rates of becoming chronic, highlighting the importance of considering the risks of chronic irAEs in treatment decision-making.

JAMA ONCOLOGY (2021)

添加到收藏夹

Article Medicine, Research & Experimental

Obesity results in adipose tissue T cell exhaustion

Cara E. Porsche et al.

Summary: Obese visceral white adipose tissue ATTs exhibited impaired inflammatory characteristics upon stimulation, potentially influenced by both environmental and cell-intrinsic factors, suggesting functional abnormalities in obesity-induced ATTs.

JCI INSIGHT (2021)

添加到收藏夹

Article Oncology

Immune checkpoint inhibitor associated vitiligo and its impact on survival in patients with metastatic melanoma: an Italian Melanoma Intergroup study

M. Guida et al.

Summary: Among VLD patients, certain features may help identify those who respond effectively to immunotherapy, enabling clinicians to make more appropriate decisions regarding therapeutic options and duration.

ESMO OPEN (2021)

添加到收藏夹

Article Oncology

Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti-PD-1 Monotherapy

Xue Bai et al.

Summary: A multicenter retrospective analysis found that early high-dose GCC use was associated with poorer survival outcomes in melanoma patients after anti-PD-1 monotherapy, highlighting the need for cautious use of GCC. These findings were validated in a combined validation cohort, confirming the association between high-dose GCC use and worse prognosis.

CLINICAL CANCER RESEARCH (2021)

添加到收藏夹

Article Oncology

Original Research Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy

Helen Dearden et al.

Summary: Combination ipilimumab and nivolumab therapy for metastatic melanoma patients may lead to hyperacute toxicity, requiring varying degrees of immunosuppression; some patients may require prolonged immunosuppression and remain at risk of further severe toxicity. The outcomes of such patients appear to be similar to those of trial populations.

EUROPEAN JOURNAL OF CANCER (2021)

添加到收藏夹

Article Oncology

Male fertility during and after immune checkpoint inhibitor therapy: A cross-sectional pilot study

Martin Salzmann et al.

Summary: This study aimed to assess male infertility after initiation of ICI treatment, with results showing that most patients had no restrictions in fertility, but some may experience inflammatory loss of spermatogenesis. Cryopreservation should be discussed with all patients with potential future desire for children before treatment.

EUROPEAN JOURNAL OF CANCER (2021)

添加到收藏夹

Article Endocrinology & Metabolism

Metabolic disease and adverse events from immune checkpoint inhibitors

Amanda Leiter et al.

Summary: Overweight cancer patients with fewer metabolic comorbidities are at increased risk for immune-related adverse events (irAEs). This study highlights the importance of evaluating body mass index (BMI) in conjunction with associated metabolic comorbidities in assessing the risk of irAE development and immune checkpoint inhibitor (ICI) response.

EUROPEAN JOURNAL OF ENDOCRINOLOGY (2021)

添加到收藏夹

Meeting Abstract Oncology

Five-year survival outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC: An update from the PACIFIC trial.

David R. Spigel et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade

Miles C. Andrews et al.

Summary: The study showed that tumor-associated immune and genomic biomarkers of response to combined immune checkpoint blockade (CICB) in melanoma patients were similar to those of monotherapy, while toxicity from CICB was associated with a more diverse peripheral T-cell repertoire. Additionally, analysis of gut microbiota revealed a higher abundance of Bacteroides intestinalis in patients experiencing toxicity, along with an upregulation of the inflammatory factor IL-1 beta in colitis samples.

NATURE MEDICINE (2021)

添加到收藏夹

Article Ophthalmology

Ophthalmic Immune-Related Adverse Events after Anti-CTLA-4 or PD-1 Therapy Recorded in the American Academy of Ophthalmology Intelligent Research in Sight Registry

Michel M. Sun et al.

Summary: The study focused on ophthalmic immune-related adverse events in cancer immunotherapy patients, determining the incidence and recurrence rates. Findings highlighted the importance of ophthalmic specialist care coordination for patients initiating immune checkpoint inhibitor therapy, especially those with a history of autoimmune ocular diseases, due to elevated rates of ophthalmic immune-related AEs and high risk of recurrence.

OPHTHALMOLOGY (2021)

添加到收藏夹

Article Cell Biology

Immune checkpoint blockade reprograms systemic immune landscape and tumor microenvironment in obesity-associated breast cancer

Ajeeth K. Pingili et al.

Summary: Obesity may enhance the efficacy of immune checkpoint therapies in breast cancer, leading to differential responses to anti-PD-1 treatment in lean and obese mice.

CELL REPORTS (2021)

添加到收藏夹

Article Oncology

Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors

Amanda C. Guidon et al.

Summary: This study aimed to develop consensus guidance and definitions for irAE-Ns, using a modified Delphi consensus process and the RAND/University of California Los Angeles Appropriateness Method, resulting in consensus definitions for seven core disorders. These definitions standardized irAE-N classification, providing guidance for clinical and research settings.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

添加到收藏夹

Article Oncology

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events

Julie R. Brahmer et al.

Summary: ICIs are standard treatments for cancer, but come with risks of immune-related adverse events. The SITC convened an expert panel to develop guidelines for managing irAEs, aiming to improve patient outcomes through evidence-based recommendations.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

添加到收藏夹

Article Oncology

Resident and circulating memory T cells persist for years in melanoma patients with durable responses to immunotherapy

Jichang Han et al.

Summary: The study analyzed exceptional responders to checkpoint blockade for melanoma and found long-lasting tissue-resident memory and effector memory T-cell clonotypes in skin and blood. These clonotypes with tumor-related immunity memory could serve as a prognostic value for patients with melanoma.

NATURE CANCER (2021)

添加到收藏夹

Letter Oncology

Myocarditis Surveillance With High-Sensitivity Troponin I During Cancer Treatment With Immune Checkpoint Inhibitors

Sarah Waliany et al.

JACC: CARDIOONCOLOGY (2021)

添加到收藏夹

Article Oncology

A multicenter characterization of hepatitis associated with immune checkpoint inhibitors

J. Randall Patrinely et al.

Summary: Immune-related hepatitis associated with immune checkpoint inhibitors has a median onset time of around two months, with most patients being asymptomatic or experiencing flu-like symptoms. Treatment usually involves glucocorticoids and second-line immunosuppression, with a modest risk of hepatitis recurrence when rechallenging with ICI therapy.

ONCOIMMUNOLOGY (2021)

添加到收藏夹

Article Endocrinology & Metabolism

Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment

Christopher A. Muir et al.

Summary: Thyroid dysfunction is common following immune checkpoint inhibition, with distinct phenotypes of thyroid irAEs showing unique clinical and biochemical associations. Overt thyrotoxicosis was associated with longer survival outcomes, while no association was found between hypothyroidism and cancer outcomes.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2021)

添加到收藏夹

Review Endocrinology & Metabolism

THYROID DYSFUNCTION, RECOVERY, AND PROGNOSIS IN MELANOMA PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: A RETROSPECTIVE REVIEW

Mazen Al Mushref et al.

ENDOCRINE PRACTICE (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

CD8+ T cells regulate liver injury in obesity-related nonalcoholic fatty liver disease

Denitra A. Breuer et al.

AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2020)

添加到收藏夹

Article Oncology

Health care utilization and steroid-refractory toxicities from immune checkpoint inhibitors

Laura X. Wang et al.

CANCER (2020)

添加到收藏夹

Article Oncology

The Impact of Nonsteroidal Anti-Inflammatory Drugs, Beta Blockers, and Metformin on the Efficacy of Anti-PD-1 Therapy in Advanced Melanoma

Daniel Y. Wang et al.

ONCOLOGIST (2020)

添加到收藏夹

Article Oncology

Predominance of Central Memory T Cells with High T-Cell Receptor Repertoire Diversity is Associated with Response to PD-1/PD-L1 Inhibition in Merkel Cell Carcinoma

Ivelina Spassova et al.

CLINICAL CANCER RESEARCH (2020)

添加到收藏夹

Review Pharmacology & Pharmacy

Neurologic complications of immune checkpoint inhibitors

Alexandra M. Haugh et al.

EXPERT OPINION ON DRUG SAFETY (2020)

添加到收藏夹

Article Oncology

Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609

Ahmad A. Tarhini et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Long-Term Outcomes and Responses to Retreatment in Patients With Melanoma Treated With PD-1 Blockade

Allison Betof Warner et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease

Hamzah Abu-Sbeih et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Urology & Nephrology

Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI: A Multicenter Study

Frank B. Cortazar et al.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2020)

添加到收藏夹

Article Oncology

Management of Immunotherapy-Related Toxicities, Version 1.2020 Featured Updates to the NCCN Guidelines

John A. Thompson et al.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2020)

添加到收藏夹

Review Oncology

The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature

Vivek Kumar et al.

ONCOLOGIST (2020)

添加到收藏夹

Article Oncology

Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo A Secondary Analysis of a Randomized Clinical Trial

Alexander M. M. Eggermont et al.

JAMA ONCOLOGY (2020)

添加到收藏夹

Article Biology

Anti-PD-1 immunotherapy leads to tuberculosis reactivation via dysregulation of TNF-α

Liku B. Tezera et al.

ELIFE (2020)

添加到收藏夹

Article Oncology

Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events

Alessio Cortellini et al.

EUROPEAN JOURNAL OF CANCER (2020)

添加到收藏夹

Article Oncology

Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasis

Eleftheria Chorti et al.

EUROPEAN JOURNAL OF CANCER (2020)

添加到收藏夹

Article Urology & Nephrology

Early T cell infiltration is modulated by programed cell death-1 protein and its ligand (PD-1/PD-L1) interactions in murine kidney transplants

Young Jun Shim et al.

KIDNEY INTERNATIONAL (2020)

添加到收藏夹

Article Oncology

Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer

Charles Dolladille et al.

JAMA ONCOLOGY (2020)

添加到收藏夹

Article Oncology

COVID-19 and immune checkpoint inhibitors: initial considerations

Ryan J. Sullivan et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

添加到收藏夹

Article Oncology

Immune Checkpoint Inhibitor-Associated Primary Adrenal Insufficiency: WHO VigiBase Report Analysis

Virginie Grouthier et al.

ONCOLOGIST (2020)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Cardiovascular Health and Outcomes in Cancer Patients Receiving Immune Checkpoint Inhibitors

Ohad Oren et al.

AMERICAN JOURNAL OF CARDIOLOGY (2020)

添加到收藏夹

Review Oncology

Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy

J. Haanen et al.

ANNALS OF ONCOLOGY (2020)

添加到收藏夹

Review Immunology

Rheumatic immune-related adverse events associated with cancer immunotherapy: A nationwide multi-center cohort

Janet Roberts et al.

AUTOIMMUNITY REVIEWS (2020)

添加到收藏夹

Review Immunology

Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities

Yves Allenbach et al.

AUTOIMMUNITY REVIEWS (2020)

添加到收藏夹

Article Oncology

Survivorship in immune therapy: Assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand

James Randall Patrinely et al.

EUROPEAN JOURNAL OF CANCER (2020)

添加到收藏夹

Letter Dermatology

Diagnostic and therapeutic differences between immune checkpoint inhibitor-induced and idiopathic bullous pemphigoid: a cross-sectional study

G. E. Molina et al.

BRITISH JOURNAL OF DERMATOLOGY (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy

Adrienne M. Luoma et al.

CELL (2020)

添加到收藏夹

Letter Oncology

Association of Impaired Spermatogenesis With the Use of Immune Checkpoint Inhibitors in Patients With Metastatic Melanoma

Jason M. Scovell et al.

JAMA ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Immune checkpoint inhibitor-associated celiac disease

Yousef Badran et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

添加到收藏夹

Article Oncology

Impact of body composition on outcomes from anti-PD1+/- anti-CTLA-4 treatment in melanoma

Arissa C. Young et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

添加到收藏夹

Article Oncology

Outcomes after resumption of immune checkpoint inhibitor therapy after high-grade immune-mediated hepatitis

Michael Li et al.

CANCER (2020)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque

Zsofia D. Drobni et al.

CIRCULATION (2020)

添加到收藏夹

Article Oncology

Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153

David M. Waterhouse et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial

Alexander M. M. Eggermont et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial

Paolo A. Ascierto et al.

LANCET ONCOLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma

Reinhard Dummer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Oncology

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial

Laurence Albiges et al.

ESMO OPEN (2020)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Management of Acute Myocarditis and Chronic Inflammatory Cardiomyopathy An Expert Consensus Document

Enrico Ammirati et al.

CIRCULATION-HEART FAILURE (2020)

添加到收藏夹

Article Oncology

Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials

Bin Zhao et al.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2020)

添加到收藏夹

Article Rheumatology

Immune checkpoint inhibitor-induced inflammatory arthritis: a qualitative study identifying unmet patient needs and care gaps

Laura C. Cappelli et al.

BMC RHEUMATOLOGY (2020)

添加到收藏夹

Article Oncology

Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade

Chipman R. G. Stroud et al.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2019)

添加到收藏夹

Article Oncology

Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma

Y. J. L. Jansen et al.

ANNALS OF ONCOLOGY (2019)

添加到收藏夹

Review Endocrinology & Metabolism

A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors

Jeroen de Filette et al.

HORMONE AND METABOLIC RESEARCH (2019)

添加到收藏夹

Article Oncology

Hematologic Complications of Immune Checkpoint Inhibitors

Elizabeth J. Davis et al.

ONCOLOGIST (2019)

添加到收藏夹

Article Multidisciplinary Sciences

PD-1/PD-L1 checkpoint blockade harnesses monocyte-derived macrophages to combat cognitive impairment in a tauopathy mouse model

Neta Rosenzweig et al.

NATURE COMMUNICATIONS (2019)

添加到收藏夹

Review Rheumatology

Immune Checkpoint Inhibitor-Induced Myositis: a Case Report and Literature Review

Hiroko Kadota et al.

CURRENT RHEUMATOLOGY REPORTS (2019)

添加到收藏夹

Article Oncology

A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable

Alessio Cortellini et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)

添加到收藏夹

Meeting Abstract Oncology

Interleukin-6 is potential target to de-couple checkpoint inhibitor-induced colitis from antitumor immunity.

Daniel H. Johnson et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy

Blake M. Warner et al.

ONCOLOGIST (2019)

添加到收藏夹

Article Oncology

The Impact of High-Dose Glucocorticoids on the Outcome of Immune-Checkpoint Inhibitor-Related Thyroid Disorders

Chanjuan Ma et al.

CANCER IMMUNOLOGY RESEARCH (2019)

添加到收藏夹

Article Oncology

Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer

Fiamma Berner et al.

JAMA ONCOLOGY (2019)

添加到收藏夹

Letter Oncology

Association of Anti-Programmed Cell Death 1 Cutaneous Toxic Effects With Outcomes in Patients With Advanced Melanoma

Henry T. Quach et al.

JAMA ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study

Douglas B. Johnson et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Myocarditis in the Setting of Cancer Therapeutics Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology

Marc P. Bonaca et al.

CIRCULATION (2019)

添加到收藏夹

Article Endocrinology & Metabolism

Checkpoint Inhibitor-Associated Autoimmune Diabetes Is Distinct From Type 1 Diabetes

Venessa H. M. Tsang et al.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)

添加到收藏夹

Article Oncology

Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis

Hamzah Abu-Sbeih et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Five-Year Overall Survival for Patients With Advanced Non-Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study

Edward B. Garon et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Treatment Outcomes of Immune-Related Cutaneous Adverse Events

Gregory S. Phillips et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

添加到收藏夹

Article Biochemistry & Molecular Biology

A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis

Douglas B. Johnson et al.

NATURE MEDICINE (2019)

添加到收藏夹

Letter Medicine, General & Internal

Alemtuzumab for Immune-Related Myocarditis Due to PD-1 Therapy

Khashayar Esfahani et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Letter Medicine, General & Internal

Abatacept for Severe Immune Checkpoint Inhibitor-Associated Myocarditis

Joe-Elie Salem et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Article Oncology

Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab

Suzanne L. Topalian et al.

JAMA ONCOLOGY (2019)

添加到收藏夹

Article Endocrinology & Metabolism

Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis

Alexander Faje et al.

EUROPEAN JOURNAL OF ENDOCRINOLOGY (2019)

添加到收藏夹

Article Clinical Neurology

Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies

Divyanshu Dubey et al.

NEUROLOGY (2019)

添加到收藏夹

Article Medicine, General & Internal

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

J. Larkin et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Article Oncology

Anti-PD-1-Induced Pneumonitis Is Associated with Persistent Imaging Abnormalities in Melanoma Patients

Douglas B. Johnson et al.

CANCER IMMUNOLOGY RESEARCH (2019)

添加到收藏夹

Article Oncology

Concurrent therapy with immune checkpoint inhibitors and TNFα blockade in patients with gastrointestinal immune-related adverse events

Yousef R. Badran et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)

添加到收藏夹

Review Oncology

Reactivation of tuberculosis in cancer patients following administration of immune checkpoint inhibitors: current evidence and clinical practice recommendations

Amalia Anastasopoulou et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)

添加到收藏夹

Article Biochemistry & Molecular Biology

Single-cell immune landscape of human atherosclerotic plaques

Dawn M. Fernandez et al.

NATURE MEDICINE (2019)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Cancer Treatment-Associated Pericardial Disease: Epidemiology, Clinical Presentation, Diagnosis, and Management

Chandra K. Ala et al.

CURRENT CARDIOLOGY REPORTS (2019)

添加到收藏夹

Review Oncology

Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors

Satya Das et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)

添加到收藏夹

Article Oncology

T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028

Patrick A. Ott et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

添加到收藏夹

Review Oncology

Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Neurologic Toxicity: Illustrative Case and Review of the Literature

Kerry L. Reynolds et al.

ONCOLOGIST (2019)

添加到收藏夹

Article Multidisciplinary Sciences

Immune check point inhibitors-induced hypophysitis: a retrospective analysis of the French Pharmacovigilance database

Julie Garon-Czmil et al.

SCIENTIFIC REPORTS (2019)

添加到收藏夹

Article Immunology

Defining 'T cell exhaustion'

Christian U. Blank et al.

NATURE REVIEWS IMMUNOLOGY (2019)

添加到收藏夹

Article Medicine, General & Internal

Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs

Alyson Haslam et al.

JAMA NETWORK OPEN (2019)

添加到收藏夹

Correction Oncology

Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (vol 28, pg 119, 2017)

J. B. A. G. Haanen et al.

ANNALS OF ONCOLOGY (2018)

添加到收藏夹

Article Oncology

High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma

Alexander T. Faje et al.

CANCER (2018)

添加到收藏夹

Article Endocrinology & Metabolism

Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors

Angeliki Stamatouli et al.

DIABETES (2018)

添加到收藏夹

Article Medicine, Research & Experimental

Early B cell changes predict autoimmunity following combination immune checkpoint blockade

Rituparna Das et al.

JOURNAL OF CLINICAL INVESTIGATION (2018)

添加到收藏夹

Article Oncology

Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma

Caroline Robert et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Myocarditis in Patients Treated With Immune Checkpoint Inhibitors

Syed S. Mahmood et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)

添加到收藏夹

Letter Medicine, General & Internal

Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis

Javid J. Moslehi et al.

LANCET (2018)

添加到收藏夹

Article Oncology

Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis

Jennifer L. McQuade et al.

LANCET ONCOLOGY (2018)

添加到收藏夹

Article Medicine, General & Internal

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

R. J. Motzer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Review Medicine, General & Internal

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade

Michael A. Postow et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Review Multidisciplinary Sciences

Cancer immunotherapy using checkpoint blockade

Antoni Ribas et al.

SCIENCE (2018)

添加到收藏夹

Review Rheumatology

Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen

Laura C. Cappelli et al.

SEMINARS IN ARTHRITIS AND RHEUMATISM (2018)

添加到收藏夹

Article Oncology

Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC

Fernando C. Santini et al.

CANCER IMMUNOLOGY RESEARCH (2018)

添加到收藏夹

Article Endocrinology & Metabolism

Immune-Related Thyroiditis with Immune Checkpoint Inhibitors

Priyanka C. Iyer et al.

THYROID (2018)

添加到收藏夹

Review Oncology

Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors A Systematic Review and Meta-analysis

Daniel Y. Wang et al.

JAMA ONCOLOGY (2018)

添加到收藏夹

Letter Endocrinology & Metabolism

Increased Reporting of Immune Checkpoint Inhibitor-Associated Diabetes

Jordan J. Wright et al.

DIABETES CARE (2018)

添加到收藏夹

Editorial Material Medicine, General & Internal

Immune Checkpoint Inhibitor Toxicity in 2018

Douglas B. Johnson et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)

添加到收藏夹

Article Oncology

Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study

Joe-Elie Salem et al.

LANCET ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Clinical Significance of Pancreatic Atrophy Induced by Immune-Checkpoint Inhibitors: A Case-Control Study

Yael Eshet et al.

CANCER IMMUNOLOGY RESEARCH (2018)

添加到收藏夹

Article Oncology

Circulating tumor DNA predicts survival in patients with resected high-risk stage II/III melanoma

R. J. Lee et al.

ANNALS OF ONCOLOGY (2018)

添加到收藏夹

Article Medicine, Research & Experimental

Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement

Douglas B. Johnson et al.

JCI INSIGHT (2018)

添加到收藏夹

Article Oncology

Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma

M. H. Pollack et al.

ANNALS OF ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab

A. M. Menzies et al.

ANNALS OF ONCOLOGY (2017)

添加到收藏夹

Article Rheumatology

Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab

Laura C. Cappelli et al.

ANNALS OF THE RHEUMATIC DISEASES (2017)

添加到收藏夹

Article Cell Biology

Pregnancy promotes tolerance to future offspring by programming selective dysfunction in long-lived maternal T cells

Brendan M. Barton et al.

JOURNAL OF LEUKOCYTE BIOLOGY (2017)

添加到收藏夹

Article Oncology

Sarcopenic overweight is associated with early acute limiting toxicity of anti-PD1 checkpoint inhibitors in melanoma patients

Valentine Heidelberger et al.

INVESTIGATIONAL NEW DRUGS (2017)

添加到收藏夹

Article Oncology

Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy

Jarushka Naidoo et al.

JOURNAL OF CLINICAL ONCOLOGY (2017)

添加到收藏夹

Article Multidisciplinary Sciences

Chromatin states define tumour-specific T cell dysfunction and reprogramming

Mary Philip et al.

NATURE (2017)

添加到收藏夹

Article Medicine, General & Internal

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

J. Weber et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Article Medicine, General & Internal

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

J. D. Wolchok et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Letter Medicine, General & Internal

Tumor Mutational Burden and Response Rate to PD-1 Inhibition

Mark Yarchoan et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Editorial Material Oncology

Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade

Jarushka Naidoo et al.

ONCOLOGIST (2017)

添加到收藏夹

Article Multidisciplinary Sciences

Resistance to checkpoint blockade therapy through inactivation of antigen presentation

Moshe Sade-Feldman et al.

NATURE COMMUNICATIONS (2017)

添加到收藏夹

Article Oncology

Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy

Hyunju Lee et al.

CANCER IMMUNOLOGY RESEARCH (2017)

添加到收藏夹

Article Oncology

Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy

Eileen Shiuan et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)

添加到收藏夹

Article Oncology

Smoldering myocarditis following immune checkpoint blockade

Timothy G. Norwood et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)

添加到收藏夹

Article Rheumatology

Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment

Rakiba Belkhir et al.

ANNALS OF THE RHEUMATIC DISEASES (2017)

添加到收藏夹

Article Oncology

Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib

Georgina V. Long et al.

JOURNAL OF CLINICAL ONCOLOGY (2016)

添加到收藏夹

Review Cell Biology

Combinatorial approach to cancer immunotherapy: strength in numbers

Anna E. Vilgelm et al.

JOURNAL OF LEUKOCYTE BIOLOGY (2016)

添加到收藏夹

Article Biochemistry & Molecular Biology

PD-1 immune checkpoint blockade reduces pathology and improves memory in mouse models of Alzheimer's disease

Kuti Baruch et al.

NATURE MEDICINE (2016)

添加到收藏夹

Article Medicine, General & Internal

Fulminant Myocarditis with Combination Immune Checkpoint Blockade

Douglas B. dbj Johnson et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

添加到收藏夹

Review Medicine, General & Internal

Cardiovascular Toxic Effects of Targeted Cancer Therapies

Javid J. Moslehi

NEW ENGLAND JOURNAL OF MEDICINE (2016)

添加到收藏夹

Article Multidisciplinary Sciences

Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis

Krista Dubin et al.

NATURE COMMUNICATIONS (2016)

添加到收藏夹

Article Oncology

Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders

Douglas B. Johnson et al.

JAMA ONCOLOGY (2016)

添加到收藏夹

Article Oncology

Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors

Amita Patnaik et al.

CLINICAL CANCER RESEARCH (2015)

添加到收藏夹

Article Oncology

Myasthenia Gravis Induced by Ipilimumab in Patients With Metastatic Melanoma

Douglas B. Johnson et al.

JOURNAL OF CLINICAL ONCOLOGY (2015)

添加到收藏夹

Article Medicine, General & Internal

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

R. J. Motzer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

添加到收藏夹

Article Medicine, General & Internal

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

J. Larkin et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

添加到收藏夹

Article Clinical Neurology

PD-L1 Monoclonal Antibody Treats Ischemic Stroke by Controlling Central Nervous System Inflammation

Sheetal Bodhankar et al.

STROKE (2015)

添加到收藏夹

Article Oncology

Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral Center

Douglas B. Johnson et al.

CANCER IMMUNOLOGY RESEARCH (2015)

添加到收藏夹

Article Cell Biology

Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody

Shintaro Iwama et al.

SCIENCE TRANSLATIONAL MEDICINE (2014)

添加到收藏夹

Article Oncology

Opportunistic infections in patients treated with immunotherapy for cancer

Chrisann Kyi et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)

添加到收藏夹

Editorial Material Medicine, General & Internal

The Cardiovascular Perils of Cancer Survivorship

Javid Moslehi

NEW ENGLAND JOURNAL OF MEDICINE (2013)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Cardiovascular complications associated with novel angiogenesis inhibitors: Emerging evidence and evolving perspectives

Steven M. Bair et al.

TRENDS IN CARDIOVASCULAR MEDICINE (2013)

添加到收藏夹

Article Oncology

Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells

Mark J. Selby et al.

CANCER IMMUNOLOGY RESEARCH (2013)

添加到收藏夹

Review Oncology

The blockade of immune checkpoints in cancer immunotherapy

Drew M. Pardoll

NATURE REVIEWS CANCER (2012)

添加到收藏夹

Article Clinical Neurology

Programmed Death-1 Pathway Limits Central Nervous System Inflammation and Neurologic Deficits in Murine Experimental Stroke

Xuefang Ren et al.

STROKE (2011)

添加到收藏夹

Article Oncology

Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

Julie R. Brahmer et al.

JOURNAL OF CLINICAL ONCOLOGY (2010)

添加到收藏夹

Article Medicine, General & Internal

Reduced Mortality after Allogeneic Hematopoietic-Cell Transplantation.

Ted A. Gooley et al.

NEW ENGLAND JOURNAL OF MEDICINE (2010)

添加到收藏夹

Article Medicine, General & Internal

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

F. Stephen Hodi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2010)

添加到收藏夹

Article Oncology

Lung Adjuvant Cisplatin Evaluation: A pooled analysis by the LACE collaborative group

Jean-Pierre Pignon et al.

JOURNAL OF CLINICAL ONCOLOGY (2008)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Endothelial programmed death-1 ligand 1 (PD-L1) regulates CD8+ T-cell-mediated injury in the heart

Nir Grabie et al.

CIRCULATION (2007)

添加到收藏夹

Article Medicine, Research & Experimental

Proatherogenic immune responses are regulated by the PD-1/PD-L pathway in mice

Israel Gotsman et al.

JOURNAL OF CLINICAL INVESTIGATION (2007)

添加到收藏夹

Article Surgery

One thousand consecutive pancreaticoduodenectomies

JL Cameron et al.

ANNALS OF SURGERY (2006)

添加到收藏夹

Article Multidisciplinary Sciences

Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice

H Nishimura et al.

SCIENCE (2001)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.